유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - antiġeni tal-herpesvirus tal-klieb (strain f205) - immunoloġiċi għall-canidae - klieb - immunizzazzjoni attiva ta 'klieb nisa biex jipprevjenu l-mortalità, sinjali kliniċi u leżjonijiet fi ġriewi li jirriżultaw minn infezzjonijiet tal-virus tal-herpes tal-klieb akkwistati fl-ewwel ftit jiem tal-ħajja.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - e. coli adhesin f4 (f4ab, f4ac, f4ad), e. coli adhesin f5, e. coli adhesin f6, e. coli adhesin f41 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - sows; sows (nullipar) - tnaqqis ta 'enterotossikożi tat-twelid tal-ħnienes, ikkawżat minn e. coli strains, li jesprimu l-adesini f4ab, f4ac, f4ad, f5, f6 u f41, matul l-ewwel jiem tal-ħajja.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. Ġew murija onsets ta 'immunità ġimgħa wara l-kors ta' tilqim primarju għal rinotrakeite, kaliċivirus, chlamydophila felis u komponenti panleucopenia. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunoloġiċi għall-felini, - qtates - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - trajenta huwa indikat fit-trattament tad-dijabete tat-tip 2 mellitus biex itejbu l-kontroll gliċemiku fl-adulti:kif monotherapyin pazjenti li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju waħidhom u li għalihom metformin mhux adattat minħabba l-intolleranza, jew kontra-indikat minħabba l-indeboliment tal-kliewi. bħala kombinazzjoni therapyin flimkien ma 'metformin meta d-dieta u l-eżerċizzju flimkien ma' metformin waħdu ma jipprovdux kontroll gliċemiku adegwat. f'kombinazzjoni ma ' sulphonylurea u metformin meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn il-prodotti mediċinali ma jipprovdux kontroll gliċemiku adegwat. flimkien ma 'l-insulina bi jew mingħajr metformin, meta dan ir-reġim waħdu, ma' dieta u eżerċizzju, ma jipprovdux kontroll gliċemiku adegwat.

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloġiċi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

teva gmbh - dimetil fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressanti - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

roche registration gmbh - trastuzumab - stomach neoplasms; breast neoplasms - aġenti antineoplastiċi - tas-sider cancermetastatic tas-sider cancerherceptin huwa indikat għall-kura ta 'pazjenti b'her2 pożittiv għall-kanċer metastatiku tas-sider:bħala monoterapija għall-kura ta' dawk il-pazjenti li rċevew mill-anqas żewġ dożaġġi ta ' kimoterapija għall-mard metastatiku. l-kimoterapija qabel, għandu jinkludi mill-inqas anthracycline u taxane sakemm il-pazjenti mhumiex tajbin għal dawn it-trattamenti. l-ormon tat-riċettur tal-pazjenti pożittivi għall-wkoll iridu jkunu fallew it-terapija ormonali, sakemm il-pazjenti mhumiex tajbin għal dawn it-trattamenti;flimkien ma 'paclitaxel għall-kura ta' dawk il-pazjenti li ma kienux ħadu kimoterapija għall-mard metastatiku u li għalihom anthracycline mhix xierqa;f'kombinazzjoni ma 'docetaxel għall-kura ta' dawk il-pazjenti li ma rċevewx il-kimoterapija għal mard metastatiku;f'kumbinazzjoni ma 'inibitur aromatase għall-kura ta' pazjenti bl-ormon tat-riċettur pożittivi għall-kanċer tas-sider metastatiku, li ma ġietx ikkurata qabel ma ' trastuzumab. tas-sider bikri cancerherceptin huwa indikat għall-kura ta 'pazjenti b'her2 pożittiv għall-kanċer tas-sider bikri:wara l-kirurġija, kemoterapija (miżjuda fil-bidu jew adjuvant) u r-radjuterapija (jekk applikabbli);wara kimoterapija awżiljarja ma' doxorubicin u cyclophosphamide, f'kombinazzjoni ma 'paclitaxel jew docetaxel;flimkien mal-kimoterapija awżiljarja li jikkonsisti ta' docetaxel u carboplatin;flimkien ma miżjuda fil-bidu tal-kimoterapija segwit minn adjuvant herceptin it-terapija, għal lokalment avvanzat (inklużi infjammazzjoni) - mard jew tumuri >2 ċm fid-dijametru. herceptin għandu jintuża biss f'pazjenti b'kanċer metastatiku jew tal-kanċer tas-sider bikri li t-tumuri tagħhom jew her2 espressjoni żejda jew her2 amplifikazzjoni tal-ġene kif determinat permezz ta ' assay preċiż u validat. gastrika metastatika cancerherceptin flimkien ma 'capecitabine jew 5-fluorouracil u cisplatin huwa indikat għat-trattament ta' pazjenti b'her2 pożittiv għall-adenokarċinoma metastatika ta 'l-istonku jew ittella' mill-istonku junction li qatt ma kienu rċevew minn qabel kontra l-kanċer tat-trattament għall-marda metastatika tagħhom. herceptin għandu jintuża biss f'pazjenti b'kanċer tal-kolon metastatiku li t-tumuri tagħhom għandhom her2 espressjoni żejda kif definit mill-ihc2+ u ta'konferma sish jew Ħut riżultat, jew b'ihc3+ riżultat. 'assay preċiż u validat il-metodi għandhom jiġu użati.